Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

JSPR US Equity

Jasper Therapeutics, Inc.Health Care · Biological Products, (No Diagnostic Substances) · CIK 1788028 · FY ends Dec 31
$0.75
-0.00 (-0.45%)
USD · as of 2026-08-19 · marketstack
5 8-K filings · 1 13D · 2 13G
DateEventWhat happened / filerSource
2026-08-1713GSchedule 13G filed — ≥5% beneficial owner (passive) · by Velan Capital Investment Management LPsec.gov ↗
2026-08-148-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2026-08-038-K 5.07Submission of matters to a vote of security holderssec.gov ↗
2026-07-318-K 8.01Other eventssec.gov ↗
2026-07-2013D/ASchedule 13D amendment — ≥5% beneficial owner (active intent) · by Velan Capital Investment Management LPsec.gov ↗
2026-07-178-K 7.01Regulation FD disclosuresec.gov ↗
2026-07-178-K 5.03Amendments to articles of incorporation or bylaws; fiscal year changesec.gov ↗
2026-07-178-K 5.02Departure/election of directors or officers; compensationsec.gov ↗
2026-07-178-K 3.02Unregistered sales of equity securitiessec.gov ↗
2026-07-178-K 2.01Completion of acquisition or disposition of assetssec.gov ↗
2026-07-178-K 1.01Entry into a material definitive agreementsec.gov ↗
2026-07-168-K 7.01Regulation FD disclosuresec.gov ↗
2026-07-1013G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by INTEGRATED CORE STRATEGIES (US) LLCsec.gov ↗
Source: SEC EDGAR (public domain) · history starts 2026-07-10

Every row is a filed document, checked against its EDGAR index.